Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Xencor (NASDAQ:XNCR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and price targets for Cardiff Oncology and Xencor, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 1 | 3 | 3 | 0 | 2.29 |
| Xencor | 1 | 3 | 6 | 1 | 2.64 |
Cardiff Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 705.15%. Xencor has a consensus price target of $34.00, suggesting a potential upside of 36.33%. Given Cardiff Oncology’s higher possible upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Xencor.
Insider and Institutional Ownership
16.3% of Cardiff Oncology shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Cardiff Oncology and Xencor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -7,885.43% | -103.10% | -75.52% |
| Xencor | -155.59% | -28.66% | -20.38% |
Earnings & Valuation
This table compares Cardiff Oncology and Xencor”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $590,000.00 | 122.82 | -$45.85 million | ($0.60) | -1.55 |
| Xencor | $125.58 million | 14.77 | -$91.92 million | ($2.17) | -11.49 |
Cardiff Oncology has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cardiff Oncology has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.
Summary
Cardiff Oncology beats Xencor on 8 of the 15 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About Xencor
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
